Company presentations
Atopia Therapeutics
Atopia Therapeutics, is developing ATP-R13, a first-in-class disease-modifying oral immunotherapy targeting allergic diseases like asthma, atopic dermatitis, and food allergies. Derived from a natural bacterial protein, ATP-R13 restores immune tolerance by inducing regulatory T cells (Tregs), addressing the root cause of allergic inflammation. Atopia aims to provide curative solutions beyond symptom management and is advancing ATP-R13 toward clinical development
Date, time and room information
May 6, 13:45 - 14:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Atopia Therapeutics - Unlocking the healing power of nature for asthma & allergies
Speaker information
| Name | Position | Institution |
|---|---|---|
| Gregoire Chevalier | CEO | Atopia Therapeutics |
